drugset
drugset / Trial / NCT04185415

A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

NCT04185415 ↗

Phase 1 Completed 25 enrolled UCB Biopharma SRL
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of the study is to assess the safety and tolerability of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).

Timeline

Start
2019-12-03
Primary completion
2021-11-17
Completion
2021-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject bepranemab Monoclonal antibody — Intravenous

Indications

progressive supranuclear palsy